BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Abliva - ECPv6.15.14//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://abliva.com
X-WR-CALDESC:Events for Abliva
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221121
DTEND;VALUE=DATE:20221124
DTSTAMP:20260405T184847
CREATED:20221114T101134Z
LAST-MODIFIED:20221122T084600Z
UID:3411-1668988800-1669247999@abliva.com
SUMMARY:Mitochondrial Medicine - Therapeutic Development
DESCRIPTION:In late November\, Abliva will attend the annual scientific conference Mitochondrial Medicine – Therapeutic Development in Hinxton\, UK. \nAbliva’s Chief Medical Officer\, Magnus Hansson\, will present a poster on one of the important preparatory studies for the upcoming\, potentially registrational\, Phase 2 study\, FALCON\, with KL1333 in patients with mitochondrial diseases.
URL:https://abliva.com/event/mitochondrial-medicine-therapeutic-development-3/
LOCATION:Wellcome Genome Campus\, Hinxton\, United Kingdom
CATEGORIES:Scientific event
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2020/10/Magnus_whiteboard.jpg
END:VEVENT
END:VCALENDAR